MIA is a potential biomarker for tumour load in neurofibromatosis type 1

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Kolanczyk, Mateusz ^a,b   Mautner, Victor ^c   Kossler, Nadine ^a,b   Nguyen, Rosa ^c   Kühnisch, Jirko ^b   Zemojtel, Tomasz ^b   Jamsheer, Aleksander ^d,e   Wegener, Eike ^a,b   Thurisch, Boris ^a,b   Tinschert, Sigrid ^f   Holtkamp, Nikola ^a   Park, Su Jin ^a   Birch, Patricia ^g   Kendler, David ^g   Harder, Anja ^h   Mundlos, Stefan ^a,b   Kluwe, Lan ^c,i  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Center for Medical Genetics   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; NEUROFIBROMIN; TRANSCRIPTION FACTOR SOX9; MIA PROTEIN, HUMAN; MIA1 PROTEIN, MOUSE; SCLEROPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DYSPLASIA; CARTILAGE INJURY; CONTROLLED STUDY; DEREGULATION; FEMALE; IN SITU HYBRIDIZATION; MOUSE; NEUROFIBROMA; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; AGED; ANIMAL; C57BL MOUSE; DISEASE MODEL; HUMAN; MALE; MIDDLE AGED; NEUROFIBROMATOSIS; PATHOLOGY; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM PROTEINS; NEUROFIBROMATOSIS 1; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79959777693     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-82     Document Type: Article

References (22)

1. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33-40.
2. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 2009, 4:453-463. 10.1016/j.stem.2009.03.017, 2737469, 19427294.
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311-314. 10.1136/jmg.39.5.311, 1735122, 12011145.
4. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3:685-694. 10.1038/nrc1168, 12951587.
5. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997, 79:2125-2131. 10.1002/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N, 9179058.
6. Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 2008, 10:593-598. 10.1215/15228517-2008-011, 2666233, 18559970.
7. Mashour GA, Driever PH, Hartmann M, Drissel SN, Zhang T, Scharf B, Felderhoff-Müser U, Sakuma S, Friedrich RE, Martuza RL, Mautner VF, Kurtz A. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin Cancer Res 2004, 10:5677-5683. 10.1158/1078-0432.CCR-03-0769, 15355893.
8. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000, 5:477-485. 10.1634/theoncologist.5-6-477, 11110599.
9. Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Spörle R, Herrmann BG, Parada LF, Kornak U, Mundlos S. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007, 16:874-886. 10.1093/hmg/ddm032, 17317783.
10. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 2006, 4:441-451. 10.1016/j.cmet.2006.10.010, 2756713, 17141628.
11. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009, 1:236-248. 10.1002/emmm.200900027, 20049725.
12. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994, 54:5695-5701.
13. Vucetić B, Rogan SA, Hrabac P, Hudorović N, Cupić H, Lukinac L, Ledinsky M, Matejcić A, Lovricević I, Zekan M. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res 2008, 18:201-207. 10.1097/CMR.0b013e3283021929, 18477894.
14. Stahlecker J, Gauger A, Bosserhoff A, Büttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 2000, 20:5041-5044.
15. Hau P, Apfel R, Wiese P, Tschertner I, Blesch A, Bogdahn U. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin. Anticancer Res 2002, 22:577-583.
16. Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 2003, 83:1583-1594. 10.1097/01.LAB.0000097191.12477.5D, 14615412.
17. Bauer R, Humphries M, Fassler R, Winklmeier A, Craig SE, Bosserhoff AK. Regulation of integrin activity by MIA. J Biol Chem 2006, 281:11669-11677. 10.1074/jbc.M511367200, 16517605.
18. Winklmeier A, Contreras-Shannon V, Arndt S, Melle C, Bosserhoff AK. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration. Cancer Sci 2009, 100:261-268. 10.1111/j.1349-7006.2008.01048.x, 19200257.
19. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 2009, 250:665-673. 10.1148/radiol.2503080700, 19244040.
20. Xie WF, Zhang X, Sakano S, Lefebvre V, Sandell LJ. Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J Bone Miner Res 1999, 14:757-763. 10.1359/jbmr.1999.14.5.757, 10320524.
21. Tscheudschilsuren G, Bosserhoff AK, Schlegel J, Vollmer D, Anton A, Alt V, Schnettler R, Brandt J, Proetzel G. Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA. Exp Cell Res 2006, 312:63-72.
22. Schubert T, Schlegel J, Schmid R, Opolka A, Grassel S, Humphries M, Bosserhoff AK. Modulation of cartilage differentiation by melanoma inhibiting activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP). Exp Mol Med 2010, 42:166-174. 10.3858/emm.2010.42.3.017, 2845001, 20164682.